The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? [0.03%]
关于西米普利单抗NSCLC（来自EMPOWER-Lung 1和-Lung 3）FDA适应症中除了EGFR突变和ALK融合外的ROS1融合排除条款。免疫治疗在无吸烟史患者为主且携带可操作驱动基因突变的NSCLC中的最新科学观点更新？
Danielle Brazel,Saihong Ignatius Ou
Danielle Brazel
Cemiplimab is one of seven immune checkpoint inhibitors (ICIs) approved for the first-line (1L) treatment of advanced NSCLC in the US based on EMPOWER-Lung 1 and -Lung 3 trials. In addition to exclusion of NSCLC patients harboring EGFR muta...
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting [0.03%]
从ASCEND-5到ALUR再到ALTA-3：克唑替尼耐药后新一代ALK酪氨酸激酶抑制剂Ⅲ期随机对照临床试验的没落
Alexandria T M Lee,Saihong Ignatius Ou
Alexandria T M Lee
The competing roles of various next-generation ALK TKIs in the first and second line treatment setting of advanced ALK+ NSCLC were based on many phase 3 clinical trials in both the first-line and crizotinib-refractory settings. The approval...
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer [0.03%]
术前同步放化疗后III期非小细胞肺癌淋巴细胞减少对肿瘤反应及预后的相关性分析
Jared Deck,Marissa Hartley,Mohammad Akhter et al.
Jared Deck et al.
Background: Prior studies suggest lymphopenia, systemic immune-inflammatory index, and tumor response all impact clinical outcomes in Stage III NSCLC. We hypothesized that tumor response after CRT would be associated with...
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC [0.03%]
CheckMate-722：Nivolumab联合化疗在TKI耐药EGFR突变型NSCLC患者中的崛起与陨落
Alexandria T M Lee,Misako Nagasaka
Alexandria T M Lee
The treatment of non-small cell lung cancer (NSCLC) has increasingly been driven by the presence of targetable driver mutations, including epidermal growth factor receptor (EGFR) mutations. Tyrosine receptor inhibitors (TKIs) have subsequen...
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code [0.03%]
代码破解200：针对KRAS G12C突变型非小细胞肺癌的索托雷塞（AMG510）取得了突破性进展
Danielle Brazel,Jennifer Kim,Sai-Hong Ignatius Ou
Danielle Brazel
Per the US FDA sotorasib approval summary, KRAS G12C mutation is found in approximately 14% of adenocarcinoma of the lung, primarily in patients with a history of smoking. Until recently, targeted therapies against KRAS G12C have been large...
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code [0.03%]
突破200：Sotorasib并未破解KRASG12C难题密码
Shannon S Zhang,Alexandria Lee,Misako Nagasaka
Shannon S Zhang
Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has shown promising results in preclinical and clinical studies, granting its condit...
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review [0.03%]
液态活检基因分型在肺癌的临床效用及应用：全面综述
Maria Concetta Nigro,Paola Valeria Marchese,Chiara Deiana et al.
Maria Concetta Nigro et al.
Precision medicine has revolutionized the therapeutic management of cancer patients with a major impact on non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, where advances have been remarkable. Tissue biopsy, required fo...
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno [0.03%]
Tiragolumab（抗TIGIT）在SCLC中的应用：Skyscraper-02，一场滔天大火
Danielle Brazel,Sai-Hong Ignatius Ou,Misako Nagasaka
Danielle Brazel
Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) p...
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib [0.03%]
NSCLC中KRAS突变的长期靶向治疗：聚焦于Adagrasib
Danielle Brazel,Zhaohui Arter,Misako Nagasaka
Danielle Brazel
KRASG12C is one of the most common oncogenes in non-small cell lung cancer (NSCLC) and is associated with a poor prognosis. Historically, KRAS mutations have been difficult to target due to lack of binding sites and exceptionally high affin...
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs? [0.03%]
富蒙替尼（Af Fluxitinib，AST2818）亮点评析——三代EGFR-TKIs中的瑞士军刀（del19、L858R、T790M、Exon 20插入突变及“少见”G719X、S768I、L861Q）？
Shannon S Zhang,Sai-Hong Ignatius Ou
Shannon S Zhang
Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) treatment of advanced EGFR+ NSCLC due to statistically significant i...